Financials data is unavailable for this security.
View more
Year on year Oncology Institute Inc had net income fall from a gain of 152.00k to a loss of 83.07m despite a 28.42% increase in revenues from 252.48m to 324.24m. An increase in the cost of goods sold as a percentage of sales from 79.37% to 81.63% was a component in the falling net income despite rising revenues.
| Gross margin | 15.33% |
|---|---|
| Net profit margin | -19.81% |
| Operating margin | -17.60% |
| Return on assets | -34.94% |
|---|---|
| Return on equity | -102.71% |
| Return on investment | -41.97% |
More ▼
Cash flow in USDView more
In 2023, Oncology Institute Inc increased its cash reserves by 139.03%, or 19.48m. Cash Flow from Investing totalled 62.64m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 36.32m for operations while cash used for financing totalled 6.85m.
| Cash flow per share | -0.8801 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.3869 |
|---|---|
| Tangible book value per share | 0.0744 |
More ▼
Balance sheet in USDView more
| Current ratio | 3.31 |
|---|---|
| Quick ratio | 2.99 |
| Total debt/total equity | 3.08 |
|---|---|
| Total debt/total capital | 0.7549 |
More ▼
